Menssana Research

What Menssana Research does

Menssana Research is a privately held, for-profit diagnostic-technology company headquartered in Edgewater, New Jersey, that develops breath-based tests intended for the detection of disease. According to the firm's own positioning, it is the "leading developer of advanced new breath tests for detection of disease," framing the company within the non-invasive diagnostics segment of the life-sciences market where exhaled-breath analysis is used to identify disease-associated volatile organic compound (VOC) signatures. The company operates with a very small headcount (1-10 employees) and is privately held with no IPO, funding-round, or capital-raise information disclosed in the available data.

The underlying product platform — breath testing for disease — relies on detecting and classifying biomarker patterns in exhaled air, typically through chemical sensor arrays or mass-spectrometry readouts interpreted via computational pattern recognition. The available source material does not disclose specific product names, FDA clearance status, clinical indications targeted, sensor technology, proprietary algorithms, or underlying chemistry, so the precise technical architecture cannot be characterized beyond the general breath-diagnostic framing.

No revenue model, pricing structure, go-to-motion, customer segments, distribution channels, or partnership relationships are documented in the source material. The company appears to function as a small research-stage or specialty-commercial entity, but its commercial scale, customer base, and monetization mechanics are not supported by any observable evidence in the input data.

Name

Menssana Research

Website

https://menssanaresearch.com

Company type

Private

Headcount range

1–10 employees

Short description

Menssana Research is a privately held, Edgewater, NJ-based developer of advanced breath-based diagnostic tests for disease detection, operating with 1-10 employees in the non-invasive life-sciences diagnostics segment.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Rapid Antigen/Antibody Lateral Flow Tests (General Platform Category) (HLAHAOAH)

akta.pro secondary industry

Pulmonary Function Testing (PFT) & Respiratory Diagnostics (HLAKANAC)

Keywords

• Breath test diagnostics
• Disease detection devices
• Non-invasive diagnostics
• Medical breath analysis
• Diagnostic test development

Headquarters

HQ city

Edgewater

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Menssana Research develops advanced new breath tests designed for the detection of disease. The company focuses on creating non-invasive diagnostic tools that analyze exhaled breath to identify medical conditions, positioning itself as a developer of novel breath-based diagnostic technologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Breath tests for disease detection

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Direct peers

• Avisa Diagnostics: Avisa Diagnostics is a direct peer developing breath-based tests for bacterial lung infections, competing in the same breath-diagnostics-for-disease category Menssana targets.
• Respirix: Respirix is a direct peer building breath-based diagnostic tests, including for heart failure, using similar VOC biomarker detection principles as Menssana's breath tests.
• Spirosure: Spirosure develops breath analysis devices (e.g., for airway inflammation), making it a direct peer in the breath-based respiratory diagnostic device category where Menssana also operates.
• Owlstone Medical: Owlstone Medical is a direct peer: it develops breath biopsy diagnostics that analyze volatile organic compounds in breath for diseases such as cancer, mirroring Menssana's core breath-test approach to disease detection.
• Hound Labs: Hound Labs builds ultra-sensitive breath analyzers for substance detection, sharing Menssana's core technology foundation of capturing and analyzing trace compounds in exhaled breath.

Broad incumbents

• Quest Diagnostics: Quest Diagnostics is a broad incumbent offering an extensive menu of clinical laboratory tests; it represents the established diagnostic services ecosystem Menssana would need to partner with or compete against for clinical adoption.
• Labcorp: Labcorp is a broad incumbent clinical laboratory operator with deep physician relationships and nationwide logistics, the type of scaled channel Menssana would need to reach routine clinical use.

Emerging players

• CAIRE Diagnostics: CAIRE Diagnostics is an emerging player in breath-based disease detection (notably lung cancer), overlapping with Menssana on the underlying VOC biomarker approach and disease focus.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/menssana-research-inc

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Menssana Research